CRISPR Therapeutics stock
CRSPNASDAQCRISPR Therapeutics AG, HealthcareISIN CH0334081137
37Score 37 out of 100, Weak
Price and trend
48 / 100
Price history
−18% in one yearThe chart shows daily closes over 10 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 19% below it.
Since November 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 36).
The price is 31% below its 52-week high. Largest decline in 10 years: 85% (January 2021 to April 2025).
Chart figures for advanced users
- SMA 50$52.38
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$52.58
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)36
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$42.62
- The lowest closing price of the last twelve months.
- Resistance$61.89
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- CRISPR Therapeutics AG belongs to the Biotechnology industry (Switzerland) and, with a market value of $4.13B, is number 81 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $3.51M (down 90% year on year) and a loss of $581.6M.
- MEQIRI Score 37 out of 100 (Weak): rank 595 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 37.3% a year since 2020, Biotechnology median 19.7%.Growth 70
- More cash than debtCash $2.27B, financial debt $779.83M.Stability 67
Weaknesses
- DilutionShare count up 36% since 2020.Capital allocation 18
- Loss-makingLoss of $456.14M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$379.19M over the last 12 months.Fundamentals 17
Its standout strength is growth, while fundamentals and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 36 to 37.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue fell 90% on the prior year. Up to 2022 the bars include businesses that were later spun off or sold. On a comparable basis, as restated in the SEC annual reports, revenue grew 37.3% a year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross −6537%, operating −16191%, net −16570%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is moderate; no interest coverage is reported.
Earnings
- Next earnings
- 11 Feb 2027in 91 days
- Last reported
- 2 Nov 2026EPS reported −$1.15 (expected −$1.04)below expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 4.3% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$4.50−1.8%
- Revenue
- $34.15M−12.9%
- Earnings per share
- −$3.55−4.3%
- Revenue
- $119.98M−10.6%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 5 insiders sold, $5.09M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Kulkarni SamarthSale
19 Oct 2026, Chief Executive Officer
- Shares
- 47,837
- Price
- $49.78
- Value
- $2.38M
- George SimeonSale
14 Oct 2026, Board
- Shares
- 14,514
- Price
- $49.63
- Value
- $720,373
- Kasinger James R.Sale
14 Oct 2026, General Counsel and Secretary
- Shares
- 1,040
- Price
- $49.26
- Value
- $51,230
Show 5 more
- Kulkarni SamarthSale
14 Oct 2026, Chief Executive Officer
- Shares
- 4,098
- Price
- $49.26
- Value
- $201,867
- Kasinger James R.Sale
6 Oct 2026, General Counsel and Secretary
- Shares
- 1,990
- Price
- $60.04
- Value
- $119,481
- Kasinger James R.Sale
22 Sept 2026, General Counsel and Secretary
- Shares
- 10,400
- Price
- $60.24
- Value
- $626,460
- Behbahani AliSale
17 Sept 2026, Board
- Shares
- 13,679
- Price
- $57.09
- Value
- $780,935
- Patel NaimishSale
29 May 2026, Chief Medical Officer
- Shares
- 3,786
- Price
- $55.62
- Value
- $210,577
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at CRISPR Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 37
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Travere TherapeuticsTVTX $5B50
- Adaptive BiotechnologiesADPT $4.85B47
- Ionis PharmaceuticalsIONS $4.72B32
- Definium TherapeuticsDFTX $4.63B41
- CamurusCAMX.ST $4.42B74
- Relay TherapeuticsRLAY $4.36B46
- Tango TherapeuticsTNGX $4.34B45
- Xenon PharmaceuticalsXENE $4.14B37
ETFs that hold CRISPR Therapeutics
Held by 16 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Genomics & Biotechnology UCITS ETFGN0M | 2.50% | 0.50% | €127.06M |
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 1.54% | 0.49% | €318.39M |
| iShares Ageing Population UCITS ETF2B77 | 0.42% | 0.40% | €807M |
Show 5 more
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.31% | 0.35% | €1.21B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.19% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.15% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.14% | 0.30% | €4.22B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.05% | 0.43% | €2.48B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Aug 2022)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.